Pomerantz Law Firm Warns Investors About Class Action Lawsuit Against REGENXBIO Inc.

Pomerantz Law Firm Issues Investor Alert Regarding REGENXBIO

In a significant legal move affecting investors, Pomerantz LLP has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX). This action arises from possible securities fraud and other unlawful business practices allegedly involving the company and some of its executives.

The firm urges investors who have suffered losses due to their investments in REGENXBIO to act quickly, as there are critical upcoming deadlines. Interested parties must contact Pomerantz by April 14, 2026, if they wish to be appointed as Lead Plaintiff for the class action. To facilitate this, investors are encouraged to reach out to Danielle Peyton via email at [email protected] or through the toll-free number 888.4-POMLAW (extension 7980). Providing essential details such as mailing address, phone numbers, and the number of shares purchased will be crucial for their claims.

The complaint highlights serious issues triggered by a press release from REGENXBIO on January 28, 2026. The company announced that the U.S. FDA placed a clinical hold on its investigational gene therapy RGX-111 for treating MPS I (Hurler syndrome). This decision followed preliminary analyses concerning a case of neoplasm observed in a participant during the Phase I/II study. The FDA also extended this hold to RGX-121, developed for MPS II (Hunter Syndrome), citing shared similarities in the products and clinical study populations.

This alarming development shocked investors, resulting in a steep drop in REGENXBIO's stock price, which fell by $2.40 per share, equivalent to 17.9%, settling at $11.01 by the end of that trading day. This sudden decline is a primary impetus for the class action lawsuit, as investors seek to recover their losses attributed to what they believe to be misleading statements and inadequate disclosures by the company.

Pomerantz LLP is renowned for its dedication to securities class actions and has successfully represented numerous clients over its 85-year history. Founded by the influential Abraham L. Pomerantz, the firm has maintained a reputation for fighting for the rights of shareholders, pushing back against corporate misconduct and securities fraud. They have recovered substantial damages on behalf of class members, demonstrating their commitment to investor advocacy.

As this situation unfolds, investors currently involved or affected by REGENXBIO's actions should remain vigilant and consider legal counsel to explore their options. Joining the class action could offer a pathway to recovery. For further information regarding the filing, investors can access the complaint document through Pomerantz's official website at www.pomerantzlaw.com.

Ultimately, this case underscores the importance of transparency and accountability in corporate governance. Investors are reminded to act swiftly in these matters to ensure their rights are upheld and potential claims are filed timely.